Navigation Links
Data Showing that ReGen's Colostrinin Supports Healthy Cognitive,Function Presented at the 2007 International Congress on Natural,Medicine in Australia

London, UK, June 11, 2007-ReGen is pleased to announce that a review of scientific and clinical information on Colostrinin, its nutraceutical product which the Company believes has the potential to support healthy cognitive function, was presented today at the 2007 International Congress on Natural Medicine in Surfers Paradise, Queensland, Australia by Dr Marian Kruzel, ReGen's Chief Scientific Officer.

The conference, which is being attended by key opinion leaders and practitioners of natural medicine from around the world, is being sponsored by Metagenics Inc. of California via its Australian affiliate company Health World Ltd.

Metagenics have licensed the rights to Colostrinin(TM) for the North American market and intend to introduce it in the USA as a nutritional supplement during the last quarter of 2007.

Dr. Kruzel presented both pre-clinical and human clinical data showing that Colostrinin(TM):
reduces the production of intracellular reactive oxygen species (ROS). These increase with old age and are associated with tissue and metabolic Damage prevents the aggregation of beta-amyloid and its consequent neurotoxicity. This is a protein associated with Alzheimer's disease increases the lifespan of mice prone to premature ageing by around 30% when given in the drinking water is well-tolerated and without adverse effect when given to animals at doses up to 100 times that recommended for humans daily for prolonged periods had beneficial effects on the cognitive and functional performance of around 150 human subjects in clinical trials with mild to moderate Alzheimer's disease.

Commenting after his presentation Dr. Kruzel said, 'The audience here is extraordinary, it includes physicians, health care professionals and many other disciplines concerned about wellbeing in rapidly aging societies. It is a great pleasure to have the opportunity to present our cutting edge scientific research that validates the efficacy of nutrace utical strategies in the management of neurodegenerative diseases to such an audience'.

Jeff Katke, Chairman and Chief Executive Officer of Metagenics added, 'As advocates of natural medicine we are very pleased to be close to introducing Colostrinin(TM) in the US as we see it as an important part of our science-based neurological product line and believe it will help to maintain the health of the ageing population. Today's presentation by Dr Kruzel will be useful in
communicating the benefits of Colostrinin(TM) to a wider audience'.

For further information, please contact:

Andrew Marshall
Greycoat Communications
Tel: 020 7960 6007
Mobile No: 07785 297111

Rod Venables/Cecil Jordaan
HB Corporate
Tel: 020 7510 8600

Percy Lomax
ReGen Therapeutics Plc
Tel: 020 7153 4920


Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
3. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
4. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
5. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
6. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
7. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
8. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
9. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
10. LigoCyte Pharmaceuticals Presents Data Showing Heterosubtypic Protection Against Influenza Challenge With Virus-Like Particle Immunization
11. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
Post Your Comments:
(Date:12/1/2015)... , Dec. 2, 2015  A combination of detailed ... the first time in the surgical planning for separation of ... annual meeting of the Radiological Society of North ... --> Conjoined twins, or twins whose bodies are connected, ... rates are low and separating them through surgery is extremely ...
(Date:12/1/2015)... , Dec. 1, 2015  A large study ... drug tamoxifen while taking an antidepressant found no increased ... today in The Journal of the National Cancer Institute. ... Tamoxifen is a commonly prescribed generic drug taken by ... developing a recurrence. Tamoxifen is recommended for five years, ...
(Date:12/1/2015)... Wash. and VANCOUVER , ... Committee (DMC) meeting, OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ... is continuing based on the pre-planned interim futility analysis ... review, no new safety issues were identified by the ... all analyses and final results are expected in the ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... and hematology continuing medical education (CME), today announced that the first annual School ... New York. , “The prevention, detection and treatment of gastrointestinal cancers are undergoing ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Growth in medical ... due to decreases in utilization of hospital and nonhospital care, according to a recent ... Medical Benchmarks for Louisiana, 16th Edition , found medical payments per claim with more ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... images have been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s ... America Annual Meeting from November 29 to December 4, 2015. , MED-TAB ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has ... the Radiological Society of North America (RSNA) 2015 annual meeting through December 3 ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... clinical solutions for the care management and population health arenas, is pleased to ... clinical and cost containment services, has successfully implemented the ACUITY Complete Care™ Management ...
Breaking Medicine News(10 mins):